Hiroyuki Daida

Publications (224)697.48 Total impact

• Article: Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol.

  Manabu Ogita, Katsumi Miyauchi, Tadashi Miyazaki, Ryo Naito, Hirokazu Konishi, Shuta Tsuboi, Tomotaka Dohi, Takatoshi Kasai, Takayuki Yokoyama, Shinya Okazaki, Takeshi Kurata, Hiroyuki Daida
  [show abstract] [hide abstract]
  ABSTRACT: Diabetes mellitus is recognized an independent risk factor for coronary artery disease (CAD) and mortality. Clinical trials have shown that statins significantly reduce cardiovascular events in diabetic patients. However, residual cardiovascular risk persists despite the achievement of target low-density lipoprotein cholesterol (LDL-C) levels with statin. High-density lipoprotein cholesterol (HDL-C) is an established coronary risk factor that is independent of LDL-C levels. We evaluated the impact of HDL-C on long-term mortality in diabetic patients with stable CAD who achieved optimal LDL-C. We enrolled 438 consecutive diabetic patients who were scheduled for percutaneous coronary intervention between 2004 and 2007 at our institution. We identified 165 patients who achieved target LDL-C <100 mg/dl. Patients were stratified into two groups according to HDL-C levels (low HDL-C group, baseline HDL-C <40 mg/dl; high HDL-C group, ≥40 mg/dl). Major adverse cardiac events (MACE) that included all-cause death, acute coronary syndrome, and target lesion revascularization were evaluated between the two groups. The median follow-up period was 946 days. The rate of MACE was significantly higher in diabetic patients with low-HDL-C who achieved optimal LDL-C (6.9 vs 17.9 %, log-rank P = 0.030). Multivariate Cox regression analysis showed that HDL-C is significantly associated with clinical outcomes (adjusted hazard ratio for MACE 1.33, 95 % confidence interval 1.01-1.75, P = 0.042). Low HDL-C is a residual risk factor that is significantly associated with long-term clinical outcomes among diabetic patients with stable CAD who achieve optimal LDL-C levels.
  Heart and Vessels 03/2013; · 2.05 Impact Factor
• Article: Management and Two-Year Long-Term Clinical Outcome of Acute Coronary Syndrome in Japan.

  Hiroyuki Daida, Katsumi Miyauchi, Hisao Ogawa, Hiroyoshi Yokoi, Masayasu Matsumoto, Masafumi Kitakaze, Takeshi Kimura, Tetsuo Matsubara, Yuji Ikari, Kazuo Kimura, Kengo Tsukahara, Hideki Origasa, Yoshihiro Morino, Hiroyuki Tsutsui, Masayuki Kobayashi, Takaaki Isshiki
  [show abstract] [hide abstract]
  ABSTRACT: Background: Japanese patients have been at low risk for cardiovascular events compared with Western countries, but the data regarding current treatment status and rate of subsequent atherothrombotic events after acute coronary syndrome (ACS) are limited in Japanese patients. The objective of this study was to clarify the treatment status and long-term outcomes in Japanese ACS patients. Methods and Results: The Prevention of AtherothrombotiC Incidents Following Ischemic Coronary attack (PACIFIC) registry is a multicenter, prospective observational study of Japanese ACS patients. Consecutive patients aged ≥20 years hospitalized for ACS were enrolled from 96 hospitals and followed up for 2 years (n=3,597). ST-segment elevation myocardial infarction (STEMI) was the most frequent type of ACS (59.4%). The vast majority (93.5%) of patients underwent percutaneous coronary intervention (PCI), with a success rate of 93.9%. Frequent use of guideline-recommended pharmacological treatments was also indicated. Cumulative incidence of major adverse cardiac and cerebrovascular events (MACCE) was 6.4% (7.5% for STEMI and 4.8% for non-STEMI or unstable angina), and all-cause mortality was 6.3%. Conclusions: The PACIFIC registry has identified an incidence of MACCE of 6.4% and that of mortality at 6.3% in Japanese ACS patients at 2-year follow-up. A high proportion of patients underwent PCI, and the PCI success rate was high. Proactively performed successful PCI was considered to have contributed to favorable outcomes in these patients.
  Circulation Journal 03/2013; · 3.77 Impact Factor
• Article: Effect of Long-Term Intensive Lipid-Lowering Therapy With Rosuvastatin on Progression of Carotid Intima-Media Thickness.

  Ryuji Nohara, Hiroyuki Daida, Mitsumasa Hata, Kohei Kaku, Ryuzo Kawamori, Junji Kishimoto, Masahiko Kurabayashi, Izuru Masuda, Ichiro Sakuma, Tsutomu Yamazaki, Hiroyoshi Yokoi, Masayuki Yoshida
  [show abstract] [hide abstract]
  ABSTRACT: Background: Recently, it was reported from the Justification for Atherosclerosis Regression Treatment (JART) Study that intensive therapy with rosuvastatin significantly slowed progression of carotid intima-media thickness (IMT) compared with conventional therapy with pravastatin at 12 months. To assess the long-term efficacy of intensive therapy, the present extension study was conducted. Methods and Results: Subjects in the intensive therapy group of the JART Study were asked to participate in the extension study and to continue rosuvastatin treatment. A total of 113 subjects were enrolled into the extension study and were included in the analysis. At 24 months, the mean daily dose of rosuvastatin (±SD) was 7.9±2.9mg. Mean change in mean IMT was -0.005mm (range, -0.024 to 0.015mm) at 24 months (P=0.633, compared with baseline). Rosuvastatin lowered low-density lipoprotein cholesterol (mean±SD) by 46.4±13.8% and elevated high-density lipoprotein cholesterol (mean±SD) by 8.9±24.0% at 24 months compared with baseline. Gray scale median was measured in 25 subjects. It increased by 16.93±33.12 (mean±SD) % at 12 months and by 22.50±52.83% at 24 months from baseline (P=0.017, P=0.044, respectively). Conclusions: Two-year treatment with rosuvastatin inhibited progression of carotid IMT. Rosuvastatin also improved the plaque composition, and this qualitative change occurred relatively early after starting therapy.
  Circulation Journal 03/2013; · 3.77 Impact Factor
• Article: Influencing factors on cardiac structure and function beyond glycemic control in patients with type 2 diabetes mellitus.

  Ryoko Ichikawa, Masao Daimon, Tetsuro Miyazaki, Takayuki Kawata, Sakiko Miyazaki, Masaki Maruyama, Shuo-Ju Chiang, Hiromasa Suzuki, Chiharu Ito, Fumihiko Sato, Hirotaka Watada, Hiroyuki Daida
  [show abstract] [hide abstract]
  ABSTRACT: BACKGROUND: We hypothesized that clinical factors other than glycemic control may influence abnormal cardiac function in patients with type 2 diabetes mellitus (T2DM). We aimed to investigate the independent factors for abnormal cardiac function among clinical factors in T2DM. METHODS: We studied 148 asymptomatic patients with T2DM without overt heart disease. Echocardiographic findings were compared between diabetic patients and 68 age-matched healthy subjects. Early (E) and late (A) diastolic mitral flow velocity and early diastolic mitral annular velocity (e') were measured for assessing left ventricular (LV) diastolic function. We evaluated insulin resistance, non-esterified fatty acid, high-sensitive CRP, estimated glomerular filtration rate, waist/hip ratio, abdominal visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT) and other clinical characteristics in addition to glycemic control. VAT and SAT were quantified by computed tomography. RESULTS: In T2DM, E/A and e' were significantly lower, and E/e', left atrial volume and LV mass were significantly greater than in control subjects. In multivariate liner regression analysis, VAT was an independent determinant of left atrial volume (beta =0.203, p=0.011), E/A (beta =-0.208, p=0.002), e' (beta =-0.354, p<0.001) and E/e' (beta=0.220, p=0.003). Age was also an independent determinant, whereas fasting plasma glucose and hemoglobin A1c levels were not. In addition to systolic blood pressure, waist-hip ratio (beta=0.173, p=0.024) and VAT/SAT ratio (beta=0.162, p=0.049) were independent determinants of LV mass. CONCLUSION: Excessive visceral fat accompanied by adipocyte dysfunction may play a greater role than glycemic control in the development of diastolic dysfunction and LV hypertrophy in T2DM.
  Cardiovascular Diabetology 02/2013; 12(1):38. · 3.35 Impact Factor
• Article: Impact of Intensive Lipid Lowering on Lipid Profiles Over Time and Tolerability in Stable Coronary Artery Disease: Insights From a Subanalysis of the Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects (COSMOS).

  Masaaki Kawashiri, Masakazu Yamagishi, Tomohiro Sakamoto, Tadateru Takayama, Takafumi Hiro, Hiroyuki Daida, Atsushi Hirayama, Satoshi Saito, Tetsu Yamaguchi, Masunori Matsuzaki
  [show abstract] [hide abstract]
  ABSTRACT: BACKGROUND: Previous studies have demonstrated that intensive lipid lowering using rosuvastatin results in regression of coronary plaques. However, few data exist regarding lipid profiles over time, drug tolerability and the effects of prior use of lipid lowering agents in patients on rosuvastatin treatment. Therefore, we studied these matters in a subanalysis of the Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects (COSMOS). METHODS: Rosuvastatin was titrated for 76 weeks to attain LDL-C <80 mg/dL in 213 Japanese dyslipidemic patients with CAD. Clinic visits were scheduled for every 4 weeks during the 76-week study period. Changes over time in lipid parameters, changes in those according to prior lipid-lowering therapy, and changes in those according to baseline lipid levels were evaluated in the present subanalysis. RESULTS: Overall, 126 patients completed the study. The mean rosuvastatin dose at the last observation carried forward was 16.9 mg (range, 2.5-20 mg). Rosuvastatin significantly increased HDL-C, lowered LDL-C, and improved the LDL-C/HDL-C ratio (all, P<0.0001). Increases in serum HDL-C levels were significantly greater in patients with HDL-C <40 mg/dL than in those with HDL-C ≥40 mg/dL at baseline (P=0.0005). The estimated glomerular filtration rate increased significantly by 2.84±9.01 mL/min/1.73 m(2) (P<0.0001). Of 166 adverse events in 74 patients, 113 events in 54 patients were laboratory values beyond the normal range. CONCLUSION: Rosuvastatin significantly improved lipid profiles, with an acceptable safety profile, contributing to plaque regression in Japanese patients with CAD. © 2013 Blackwell Publishing Ltd.
  Cardiovascular Therapeutics 02/2013; · 2.35 Impact Factor
• Article: Effect of cardiac rehabilitation on muscle mass, muscle strength, and exercise tolerance in diabetic patients after coronary artery bypass grafting.

  Miho Nishitani, Kazunori Shimada, Masayuki Masaki, Satoshi Sunayama, Atsumi Kume, Kosuke Fukao, Eiryu Sai, Tomo Onishi, Miki Shioya, Hiroyuki Sato, Taira Yamamoto, Atsushi Amano, Hiroyuki Daida
  [show abstract] [hide abstract]
  ABSTRACT: BACKGROUND: The effects of cardiac rehabilitation (CR) on muscle mass, muscle strength, and exercise tolerance in patients with diabetes mellitus (DM) who received CR after coronary artery bypass grafting (CABG) have not been fully elucidated. METHODS: We enrolled 78 consecutive patients who completed a supervised CR for 6 months after CABG (DM group, n=37; non-DM group, n=41). We measured mid-upper arm muscle area (MAMA), handgrip power (HGP), muscle strength of the knee extensor (Ext) and flexor (Flex), and exercise tolerance at the beginning and end of CR. RESULTS: No significant differences in confounding factors, including age, gender, ejection fraction, or number of CR sessions, were observed between the two groups. At the beginning of CR, the levels of Ext muscle strength and peak VO(2) were significantly lower in the DM group than in the non-DM group. At the end of CR, significant improvement in the levels of muscle strength, HGP, and exercise tolerance was observed in both groups. However, the levels of Ext muscle strength, HGP, peak VO(2), thigh circumference, and MAMA were significantly lower in the DM group than in the non-DM group. In addition, no significant improvement in thigh circumference and MAMA was observed in the DM group. At the end of CR, the levels of thigh circumference and MAMA correlated with Ext and Flex muscle strength as well as with HGP. Percent changes in the levels of Ext muscle strength were significantly correlated with those of MAMA and hemoglobin A1c. CONCLUSIONS: These data suggest that improvement in muscle strength may be influenced by changes in muscle mass and high glucose levels in DM patients undergoing CR after CABG. A CR program, including muscle mass intervention and blood glucose control, may improve deterioration in exercise tolerance in DM patients after CABG.
  Journal of Cardiology 01/2013; · 1.28 Impact Factor
• Article: Relationship between Advanced Glycation End Products and Plaque Progression in Patients with Acute Coronary Syndrome: The JAPAN-ACS Sub-study.

  Yoshifumi Fukushima, Hiroyuki Daida, Takeshi Morimoto, Takatoshi Kasai, Katsumi Miyauchi, Sho-Ichi Yamagishi, Masayoshi Takeuchi, Takafumi Hiro, Takeshi Kimura, Yoshihisa Nakagawa, Masakazu Yamagishi, Yukio Ozaki, Masunori Matsuzaki
  [show abstract] [hide abstract]
  ABSTRACT: BACKGROUND: The Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS) trial demonstrated that early aggressive statin therapy in patients with ACS significantly reduces plaque volume (PV). Advanced glycation end products (AGEs) and the receptors of AGEs (RAGE) may lead to angiopathy in diabetes mellitus (DM) and may affect on the development of coronary PV. The present sub-study of JAPAN-ACS investigates the association between AGEs and RAGE, and PV. METHODS: Intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) was undertaken, followed by the initiation of statin treatment (either 4 mg/day of pitavastatin or 20 mg/day of atorvastatin), in patients with ACS. In the 208 JAPAN-ACS subjects, PV using IVUS in non-culprit segment > 5 mm proximal or distal to the culprit lesion and, serum levels of AGEs and soluble RAGE (sRAGE) were measured at baseline and 8--12 months after PCI. RESULTS: At baseline, no differences in the levels of either AGEs or sRAGE were found between patients with DM and those without DM. The levels of AGEs decreased significantly with statin therapy from 8.6 +/- 2.2 to 8.0 +/- 2.1 U/ml (p < 0.001), whereas the levels of sRAGE did not change. There were no significant correlations between changes in PV and the changes in levels of AGEs as well as sRAGE. However, high baseline AGEs levels were significantly associated with plaque progression (odds ratio, 1.21; 95% confidence interval, 1.01 - 1.48; p = 0.044) even after adjusting for DM in multivariate logistic regression models. CONCLUSIONS: High baseline AGEs levels were associated with plaque progression in the JAPAN-ACS trial. This relationship was independent of DM. These findings suggest AGEs may be related to long-term glucose control and other oxidative stresses in ACS.Trial registration: NCT00242944.
  Cardiovascular Diabetology 01/2013; 12(1):5. · 3.35 Impact Factor
• Article: Red Blood Cell Distribution Width for Heart Failure.

  Yuji Nishizaki, Hiroyuki Daida
  Internal Medicine 01/2013; 52(3):417. · 0.94 Impact Factor
• Article: Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients.

  Tsutomu Yamazaki, Ryuji Nohara, Hiroyuki Daida, Mitsumasa Hata, Kohei Kaku, Ryuzo Kawamori, Junji Kishimoto, Masahiko Kurabayashi, Izuru Masuda, Ichiro Sakuma, Hiroyoshi Yokoi, Masayuki Yoshida
  [show abstract] [hide abstract]
  ABSTRACT: This paper describes a subanalysis of the JART Study comparing rosuvastatin and pravastatin treatment. A total of 314 subjects were analyzed in this subanalysis, 282 of whom were eligible for evaluation of the relationship between LDL-C and carotid mean-IMT change. In the subanalysis, we evaluated the extent to which intensive lipid-lowering therapy slowed the mean-IMT progression by a correlation analysis between LDL-C and mean-IMT change after 12 months of statin treatment. Nearly half were male (49.4%) and elderly (49.7%). The majority (84.4%) were treated for primary prevention. Patients with hypertension and diabetes mellitus accounted for 65.3% and 44.0%, respectively. At the 12-month measurement point, mean-IMT change was correlated with LDL-C (R = 0.187; P = 0.0016), LDL-C/ HDL-C ratio (R = 0.152; P = 0.0105), and non-HDL-C (R = 0.132; P = 0.0259). Mean-IMT after 12 months was divided into 4 subgroups by LDL-C at 12 months; < 80, ≥ 80 to < 100, ≥ 100 to < 120, and ≥ 120 mg/dL. A trend analysis using the Jonckheere-Terpstra test showed statistical signifi cance (P = 0.0002). Even for prevention in Japanese patients who have lower risk of atherosclerotic disease than Western patients, lowering the LDL-C level to below the therapeutic target prevented mean-IMT progression after 12 months more strongly. These findings suggest that more intensive control of LDL-C to levels lower than those in current JAS guidelines should be required to achieve slowing of progression as well as induction of regression of atherosclerosis.
  International Heart Journal 01/2013; 54(1):33-9. · 1.16 Impact Factor
• Article: Japanese Features of Native Valve Endocarditis Caused by Coagulase-negative Staphylococci: Case Reports and a Literature Review.

  Yuji Nishizaki, Shinichiro Yamagami, Yusuke Joki, Shuuhei Takahashi, Masahiro Sesoko, Haruyo Yamashita, Takayuki Yokoyama, Yuki Uehara, Hiroyuki Daida
  [show abstract] [hide abstract]
  ABSTRACT: Although coagulase-negative staphylococci (CoNS) is a frequent cause of prosthetic valve endocarditis, native valve endocarditis (NVE) caused by CoNS is not commonly seen. Its high mortality is well known; however, there are no systematic reports published in Japan. We herein report the cases of two Japanese patients with CoNS NVE who were admitted to our hospital located in Tokyo and conduct literature searches on CoNS NVE in Japan from 1983 to March 2012 using PubMed and ICHUSHI WEB (Japan Medical Abstract Society). We also summarize the features of 22 Japanese patients with CoNS NVE, including our patients.
  Internal Medicine 01/2013; 52(5):567-72. · 0.94 Impact Factor
• Article: Association between Myocardial Triglyceride Content and Cardiac Function in Healthy Subjects and Endurance Athletes.

  Eiryu Sai, Kazunori Shimada, Takayuki Yokoyama, Shuji Sato, Tetsuro Miyazaki, Makoto Hiki, Yoshifumi Tamura, Shigeki Aoki, Hirotaka Watada, Ryuzo Kawamori, Hiroyuki Daida
  [show abstract] [hide abstract]
  ABSTRACT: Ectopic fat accumulation plays important roles in various metabolic disorders and cardiovascular diseases. Recent studies reported that myocardial triglyceride (TG) content measured by proton magnetic resonance spectroscopy ((1)H-MRS) is associated with aging, diabetes mellitus, and cardiac dysfunction. However, myocardial TG content in athletes has not yet been investigated. We performed (1)H-MRS and cardiac magnetic resonance imaging in 10 male endurance athletes and 15 healthy male controls. Serum markers and other clinical parameters including arterial stiffness were measured. Cardiopulmonary exercise testing was also performed. There were no significant differences in clinical characteristics including age, anthropometric parameters, blood test results, or arterial stiffness between the two groups. Peak oxygen uptakes, end-diastolic volume (EDV), end-systolic volume (ESV), left ventricular (LV) mass, peak ejection rates and peak filling rates were significantly higher in the athlete group than in the control group (all P<0.02). Myocardial TG content was significantly lower in the athlete group than in the control group (0.60±0.20 vs. 0.89±0.41%, P<0.05). Myocardial TG content was negatively correlated with EDV (r = -0.47), ESV (r = -0.64), LV mass (r = -0.44), and epicardial fat volume (r = 0.47) (all P<0.05). In conclusion, lower levels of myocardial TG content were observed in endurance athletes and were associated with morphological changes related to physiological LV alteration in athletes, suggesting that metabolic imaging for measurement of myocardial TG content by (1)H-MRS may be a useful technique for noninvasively assessing the "athlete's heart".
  PLoS ONE 01/2013; 8(4):e61604. · 4.09 Impact Factor
• Source

  Available from: Nagomi Kurebayashi

  Article: Usefulness of running wheel for detection of congestive heart failure in dilated cardiomyopathy mouse model.

  Masami Sugihara, Fuminori Odagiri, Takeshi Suzuki, Takashi Murayama, Yuji Nakazato, Kana Unuma, Ken-Ichi Yoshida, Hiroyuki Daida, Takashi Sakurai, Sachio Morimoto, Nagomi Kurebayashi
  [show abstract] [hide abstract]
  ABSTRACT: Inherited dilated cardiomyopathy (DCM) is a progressive disease that often results in death from congestive heart failure (CHF) or sudden cardiac death (SCD). Mouse models with human DCM mutation are useful to investigate the developmental mechanisms of CHF and SCD, but knowledge of the severity of CHF in live mice is necessary. We aimed to diagnose CHF in live DCM model mice by measuring voluntary exercise using a running wheel and to determine causes of death in these mice. A knock-in mouse with a mutation in cardiac troponin T (ΔK210) (DCM mouse), which results in frequent death with a t(1/2) of 70 to 90 days, was used as a DCM model. Until 2 months of age, average wheel-running activity was similar between wild-type and DCM mice (approximately 7 km/day). At approximately 3 months, some DCM mice demonstrated low running activity (LO: <1 km/day) while others maintained high running activity (HI: >5 km/day). In the LO group, the lung weight/body weight ratio was much higher than that in the other groups, and the lungs were infiltrated with hemosiderin-loaded alveolar macrophages. Furthermore, echocardiography showed more severe ventricular dilation and a lower ejection fraction, whereas Electrocardiography (ECG) revealed QRS widening. There were two patterns in the time courses of running activity before death in DCM mice: deaths with maintained activity and deaths with decreased activity. Our results indicate that DCM mice with low running activity developed severe CHF and that running wheels are useful for detection of CHF in mouse models. We found that approximately half of ΔK210 DCM mice die suddenly before onset of CHF, whereas others develop CHF, deteriorate within 10 to 20 days, and die.
  PLoS ONE 01/2013; 8(1):e55514. · 4.09 Impact Factor
• Article: High levels of very long-chain saturated fatty acid in erythrocytes correlates with atherogenic lipoprotein profiles in subjects with metabolic syndrome.

  Rie Matsumori, Tetsuro Miyazaki, Kazunori Shimada, Atsumi Kume, Yohei Kitamura, Kyoichi Oshida, Naotake Yanagisawa, Takashi Kiyanagi, Makoto Hiki, Kosuke Fukao, Kuniaki Hirose, Hiromichi Ohsaka, Hiroshi Mokuno, Hiroyuki Daida
  [show abstract] [hide abstract]
  ABSTRACT: AIM: Very long chain saturated fatty acid (VLCFA) levels in erythrocytes are associated with metabolic syndrome (MS). However, the relationship between levels of the VLCFA ligonoceric acid (C24:0) in erythrocytes and the atherogenic lipoprotein profiles and inflammatory state in MS remain unclear. METHODS: Based on the International Diabetes Federation (IDF) definition of MS, 195 apparently healthy males were assigned to either an MS group (n=38) or a non-MS group (n=157). Fatty acid composition of erythrocytes was determined by gas liquid chromatography. RESULTS: Erythrocytes from the MS group had a significantly higher level of C24:0 than cells from the non-MS group (4.06±0.48% versus 3.88±0.34%; p=0.03). C24:0 levels were significantly correlated with several components of MS. The C24:0 levels showed a significant negative correlation with LDL and HDL particle size. Multivariate linear regression analysis showed that C24:0 levels were independently correlated with LDL particle size after adjusting for age and each MS criterion. C24:0 levels were also positively correlated with log-transformed high-sensitivity CRP levels (p=0.04). CONCLUSION: C24:0 levels in erythrocytes are associated with specific atherogenic lipoprotein profiles and inflammation status in subjects with MS.
  Diabetes research and clinical practice 11/2012; · 2.16 Impact Factor
• Article: Association between circulating matrix metalloproteinase levels and coronary plaque regression after acute coronary syndrome - Subanalysis of the JAPAN-ACS study.

  Manabu Ogita, Katsumi Miyauchi, Takeshi Morimoto, Hiroyuki Daida, Takeshi Kimura, Takafumi Hiro, Yoshihisa Nakagawa, Masakazu Yamagishi, Yukio Ozaki, Masunori Matsuzaki
  [show abstract] [hide abstract]
  ABSTRACT: BACKGROUND: Matrix metalloproteinases (MMPs) have been implicated in development of atherosclerosis. MMPs are activated in patients with acute coronary syndrome (ACS). However, little data exist regarding the correlation between circulating levels of MMPs and plaque volume (PV) in patients with ACS. We therefore evaluated the impact of MMPs on coronary PV as a post hoc analysis from the JAPAN-ACS study. METHODS: The multicenter JAPAN-ACS trial revealed that aggressive statin therapy for patients with ACS significantly reduces coronary PV determined by intravascular ultrasound (IVUS). We studied 248 ACS patients who had serial IVUS examinations over 8-12 months in the trial. For each patient, MMP-1, 2, and 3 were measured both at baseline and at study end to evaluate the correlation between the percent change of PV and MMP levels. RESULTS: MMP-3 levels were significantly decreased during the follow-up period (100 ng/mL to 73 ng/mL, p < 0.001), in contrast, MMP-1, -2 levels were significantly increased. MMP-3 levels at follow-up correlated with coronary plaque regression (p for trend = 0.016). A multivariable linear regression model showed both MMP-2 and MMP-3 levels at follow-up were independent variables for change of coronary PV (p = 0.038 and p = 0.016, respectively). CONCLUSION: Circulating MMPs levels are associated with changes in coronary plaque volume determined by serial IVUS in patients with ACS.
  Atherosclerosis 11/2012; · 3.79 Impact Factor
• Article: Increased Circulating Soluble LR11 in Patients with Acute Coronary Syndrome.

  Manabu Ogita, Katsumi Miyauchi, Tomotaka Dohi, Shuta Tsuboi, Tadashi Miyazaki, Takayuki Yokoyama, Ken Yokoyama, Kazunori Shimada, Takeshi Kurata, Meizi Jiang, Hideaki Bujo, Hiroyuki Daida
  [show abstract] [hide abstract]
  ABSTRACT: BACKGROUND: LR11 is a novel marker of intimal smooth muscle cell (SMC) proliferation. Vascular SMCs play important roles in the development of atherosclerosis interacting with macrophages in vulnerable plaque of patients with acute coronary syndrome (ACS).The present study determines whether soluble LR11 (sLR11) is associated with ACS. METHODS: We studied 100 patients with coronary artery disease (CAD) comprising 50 consecutive patients with acute coronary syndrome (ACS; mean age 62.3±13.0 y; male 78.0%) who were successfully treated with percutaneous coronary intervention and 50 age- and sex-matched stable angina pectoris (SAP) patients as control. Concentration of sLR11 was measured by sandwich enzyme-linked immunosorbent assay method. RESULTS: Circulating sLR11 was significantly increased in patients with ACS compared with SAP (9.88±2.78 vs. 8.18±1.11ng/ml, p<0.01). Multivariate logistic regression analysis indicated that sLR11 was independently associated with ACS (odds ratio (OR), sLR11 quartile increment, 2.18, 95% confidence interval (CI) 1.21-4.19, p<0.01). Among various biomarkers of acute coronary syndrome, hsCRP were significantly correlated with LR11 (r=0.480, p<0.01). CONCLUSIONS: There is a statistical significant association between LR11 and ACS and may be a useful biomarker for the development of acute coronary syndrome.
  Clinica chimica acta; international journal of clinical chemistry 11/2012; · 2.54 Impact Factor
• Article: Wavering calcified amorphous tumour of the heart in a haemodialysis patient.

  Takayuki Kawata, Hakuoh Konishi, Atsushi Amano, Hiroyuki Daida
  [show abstract] [hide abstract]
  ABSTRACT: Calcified amorphous tumour is a rare, non-neoplastic, endocardially based, intracavitary cardiac mass. This report describes a 59-year old man in whom a mobile mass was found incidentally in the heart by routine echocardiography after he had been on haemodialysis for 3 years. Transoesophageal echocardiography revealed a high-echoic swinging tumour that originated from the annulus of the anterior commissure of the mitral valve. Surgical resection was performed to prevent embolization, and his clinical course was excellent.
  Interactive cardiovascular and thoracic surgery 11/2012;
• Article: Impact of Red Blood Cell Distribution Width on Long-Term Mortality in Diabetic Patients After Percutaneous Coronary Intervention.

  Shuta Tsuboi, Katsumi Miyauchi, Takatoshi Kasai, Manabu Ogita, Tomotaka Dohi, Tadashi Miyazaki, Takayuki Yokoyama, Takahiko Kojima, Ken Yokoyama, Takeshi Kurata, Hiroyuki Daida
  [show abstract] [hide abstract]
  ABSTRACT: Background: Red blood cell distribution width (RDW) is a novel prognostic marker that reflects oxidative stress and chronic inflammation in patients with cardiovascular disease. Diabetes mellitus increases oxidative stress and vascular inflammation, which accelerate atherosclerosis. However, the relationship between RDW and long-term outcome in diabetic patients with coronary artery disease (CAD) is unclear. Methods and Results: Subjects comprised 560 consecutive diabetic patients (mean age, 66.6 years; male, 80%) with stable CAD who had undergone elective percutaneous coronary intervention (PCI). Patients were divided into 2 groups according to median RDW at baseline (13.1%): a high RDW group (mean RDW, 14.0%; interquartile range, 13.3-14.2%); and a low RDW group (mean RDW, 12.6%; interquartile range, 12.4-12.9%). All-cause mortality rates were compared between groups. Mean duration of follow up was 3.9 years. Patients with high RDW were more likely to be older, show dyslipidemia and have a lower ejection fraction and decreased hemoglobin level. Twenty-nine patients (5.2%) died during follow up. The cumulative incidence of all-cause death was significantly higher in the high RDW group than in the low RDW group (log-rank P=0.0015). Multivariate analysis identified high RDW as being associated with all-cause mortality (hazard ratio, 2.56; 95% confidence interval, 1.12-6.62; P=0.025). Conclusions: Increased RDW was significantly associated with increased long-term all-cause mortality in diabetic patients after PCI.
  Circulation Journal 10/2012; · 3.77 Impact Factor
• Article: Prognostic impact of chronic kidney disease on 10-year clinical outcomes among patients with acute coronary syndrome.

  Tomotaka Dohi, Takatoshi Kasai, Katsumi Miyauchi, Kiyoshi Takasu, Kan Kajimoto, Naozumi Kubota, Atsushi Amano, Hiroyuki Daida
  [show abstract] [hide abstract]
  ABSTRACT: BACKGROUND: Chronic kidney disease (CKD) is closely associated with a higher risk of cardiovascular disease. However, whether patients with acute coronary syndrome (ACS) and CKD are at increased risk for long-term mortality after coronary revascularization remains unknown. METHODS AND RESULTS: Data from consecutive patients with ACS who had undergone coronary revascularization, including percutaneous coronary intervention (PCI) and coronary artery bypass surgery (CABG) were analyzed. The estimated glomerular filtration rate (eGFR) was calculated using the current Japanese equation and CKD was defined as eGFR<60mL/min/1.73m(2). Among 375 enrolled patients with ACS, 75 (20.0%) had CKD. During a follow-up period of 10.0±3.4years, the total number of deaths was 80 (21.3%), of which 36 (9.6%) were due to cardiovascular causes. Kaplan-Meier analysis showed that the presence of CKD was associated with a significant increase in mortality from all causes (log-rank test, p<0.001) and cardiovascular mortality (p<0.001). Cox proportional-hazard analysis revealed that CKD increased the risk of mortality with a hazard ratio of 2.31 (95% confidence interval (CI): 1.25-4.29, p=0.008) and of cardiovascular death with a hazard ratio of 3.76 (95% CI: 1.60-8.80, p=0.002) in patients with ACS. CONCLUSIONS: CKD is a powerful determinant of long-term all-cause and cardiovascular mortality after ACS.
  Journal of Cardiology 10/2012; · 1.28 Impact Factor
• Article: [Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo Medical University].

  Katsumi Miyauchi, Hiroyuki Daida
  Nihon Naika Gakkai Zasshi 10/2012; 101(10):3002-11.
• Article: Mortality risk of triglyceride levels in patients with coronary artery disease.

  Takatoshi Kasai, Katsumi Miyauchi, Naotake Yanagisawa, Kan Kajimoto, Naozumi Kubota, Manabu Ogita, Shuta Tsuboi, Atsushi Amano, Hiroyuki Daida
  [show abstract] [hide abstract]
  ABSTRACT: OBJECTIVE: The association between triglyceride level and the risk of coronary artery disease (CAD) remains controversial. In particular, the prognostic significance of triglyceride levels in established CAD is unclear. We aimed to assess the relationship between triglyceride levels and long-term (>10 years) prognosis in a cohort of patients after complete coronary revascularisation. DESIGN: Observational cohort study. SETTING: Departments of cardiology and cardiovascular surgery in a university hospital. PATIENTS: Consecutive patients who had undergone complete revascularisation between 1984 and 1992. All patients were categorised according to the quintiles of fasting triglyceride levels at baseline. MAIN OUTCOME MEASURES: The risk of fasting triglyceride levels for all-cause and cardiac mortality was assessed by multivariable Cox proportional hazards regression analyses. RESULTS: Data from 1836 eligible patients were assessed. There were 412 (22.4%) all-cause deaths and 131 (7.2%) cardiac deaths during a median follow-up of 10.5 years. Multivariable analyses including total and high-density lipoprotein cholesterol and other covariates revealed no significant differences in linear trends for all-cause mortality according to the quintiles of triglyceride (p for trend=0.711). However, the HR increased with the triglyceride levels in a significant and dose-dependent manner for cardiac mortality (p for trend=0.031). Multivariable analysis therefore showed a significant relationship between triglyceride levels, when treated as a natural logarithm-transformed continuous variable, and increased cardiac mortality (HR 1.51, p=0.044). CONCLUSIONS: Elevated fasting triglyceride level is associated with increased risk of cardiac death after complete coronary revascularisation.
  Heart (British Cardiac Society) 09/2012; · 4.22 Impact Factor